Gemtero 1g (Gemcitabine)

Gemcitabine
Contact us for more information
Цвет:
Вариант:
Wishlist Compare
Hetero Drugs Ltd

Gemtero 1g (Gemcitabine)

ManufacturerHetero Drugs LtdBrand nameGemteroActive substanceGemcitabineStrength1gCategoryAnti CancerManufacturerHetero Healthcare Ltd

Description  of  Gemtero 1g (Gemcitabine 1g)

Gemcitabine is generic name of brand name Citafine and Gemcitabine is a cancer medicine that inhibits the growth and spread of cancer cells in the body.
Gemtero 1g (Gemcitabine 1g) administered into a vein by slow injection.
Gemtero 1g (Gemcitabine 1g) is a prescription drug which is used under the supervision of medical oncologist

INDICATIONS of  Gemtero 1g (Gemcitabine 1g)

Gemtero 1g (Gemcitabine 1g) is indicated for the treatment for Non-small cell lung cancer which is locally advanced or has spread to other areas of the body.
Gemtero 1g (Gemcitabine 1g) is indicated for the treatment for Cancer of the pancreas which is locally advanced or has spread to other areas of the body.
Gemtero 1g (Gemcitabine 1g) is indicated for the treatment for Bladder cancer that is locally advanced or has spread to other areas of the body.
Gemtero 1g (Gemcitabine 1g) is indicated for the treatment for Breast cancer that has returned or spread to other areas of the body and is not suitable for surgery, in people whose cancer has relapsed following previous chemotherapy.
Gemtero 1g (Gemcitabine 1g) is indicated for the treatment for Ovarian cancer which is locally advanced or has spread to other areas of the body.

MECHANISM OF ACTION  of  Gemtero 1g (Gemcitabine 1g)

Gemcitabine is a family of drugs called antimetabolites which inhibits the DNA production. Antimetabolites are very same to common substances within the cell. This discontinue cell growth and division, reporting in the reducing or blocking of cancer growth. Since cancer cells, in general, replicate faster and with less error-correcting than healthy cells, cancer cells are more conscious to this damage. Gemcitabine kills cancer cells go through DNA synthesis. It interferes with ribonucleotide reductase, an enzyme important to DNA combination. Because cells cannot duplicate their DNA, they cannot properly multiply, and thus die.

ADME of  Gemtero 1g (Gemcitabine 1g)

By infusion length the volume of distribution is increased Vd: 50 L/m2
Metabolized by transformed through nucleoside kinases to two active metabolites such as gemcitabine diphosphate and gemcitabine triphosphate
The drug is excreted through urine (92-98%) and Half-life of Citafine is 1.7-19.4 hr

 SIDE EFFECTS  of  Gemtero 1g (Gemcitabine 1g)

 

Common side effects :
• Cough.
• Blocked or runny nose.
• Sweating.
• Back pain.
• Myalgia.
• Chills and fever.
• Weakness
• Loss of appetite.
• Headache.
• Insomnia
• Sleepiness.
• Mouth ulcers.
• Diarrhoea or constipation.
Very common side effects :
• Dyspnea.
• Alopecia
• Allergic skin rash.
• Cold or flu-like symptoms.
• Retention of fluid in the body
• Abnormal results in liver function tests.
• blood in the urine or protein presence

PRECAUTIONS  of  Gemtero 1g (Gemcitabine 1g)

With Gemtero 1g (Gemcitabine 1g) treatment Capillary leak syndrome resulted with serious consequences; discontinue if symptoms occur
Haemolytic uremic syndrome resulted, containing fatalities; permanently stop treatment in patients with HUS or serious kidney impairment; Kidney failure may not be reversible even with stop of therapy
Drug-induced liver injury resulted, involving liver failure and death; assess hepatic function before to initiation of therapy and periodically during treatment; stop drug in patients which develop severe liver injury
When Gemtero 1g (Gemcitabine 1g) in combination with carboplatin or paclitaxel: patients should have ANC >1.5 x 10^6/mL and platelet count >10^8/mL prior to each cycle

DRUG INTERACTION of  Gemtero 1g (Gemcitabine 1g)

No drug interaction studies have been conducted

CONTRAINDICATION of  Gemtero 1g (Gemcitabine 1g)

Hypersensitivity

PREGNANCY  OF Gemtero 1g (Gemcitabine 1g)

The Gemtero 1g (Gemcitabine 1g) Pregnancy category D

When administrated to a pregnant woman will cause fetal harm to the fetus the pregnant women should be apprised of the possible hazard to a fetus.

LACTATION of Gemtero 1g (Gemcitabine 1g)

Avoid breastfeed during this treatment because the drug Gemtero 1g (Gemcitabine 1g) may excreted into breast milk

DOSAGE of  Gemtero 1g (Gemcitabine 1g)

Pancreatic cancer :
The recommended dose is 1000mg/m2 IV infusion over 30 min once weekly x 7 weeks; rest 1 week
And the dose 1000mg/m2IV once weekly for 3 weeks of each 28-day cycle
Non-small cell lung cancer:
The recommended dose is 1000mg/m2IV infusion over 30 minutes on days 1,8 and 15 of each 28-day cycle or
The recommended dose is 1250 mg/m2IV over 30 minutes on days 1 and 8 of each 21-day cycle
Administer cisplatin 100mg/m2 IV after gemcitabine on day 1
Breast cancer :
The recommended dose is 1250 mg/m2IV over 30 minutes on days 1 and 8 of each 21-day cycle
Dose with paclitaxel 175mg/m2 on day 1 as a 3-hr infusion before gemcitabine
Ovarian cancer :
The recommended dose is 1000 mg/m2IV over 30 minutes on days 1 and 8 of each 21-day cycle.
Dose with carboplatin AUC 4 on day 1 after gemcitabine

 

STORAGE  of  Gemtero 1g (Gemcitabine 1g)

The drug Gemtero 1g (Gemcitabine 1g) Store at 20 ℃ to 25 ℃ (68 ℃ to 77℉)


MISSED DOSE of  Gemtero 1g (Gemcitabine 1g)

If failed to take dose, then have the missed dose as soon as possible before next dose time reaches or skip the dose and follow the normal schedule
Consult the doctor

Brand name:
Gemtero
Active substance:
Gemcitabine
Strength:
1g
Category:
Anti Cancer
Manufacturer:
Hetero Healthcare Ltd
Packaging:
1 Vial
Product form:
Injection

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India